Evaluating the Effectiveness of Tocilizumab in Severe and Critically Ill COVID-19 Patients: A Retrospective Cohort Study | ||||
| Journal of the Medical Research Institute | ||||
| Article 1, Volume 46, Issue 2, June 2025, Page 1-9 PDF (506.41 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/jmalexu.2025.375973.1054 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Amal M. Shouair1; Ashraf AlamEldin Noah   2; Doaa Hamdy Aly 3; Eman Mahmoud Abdelrahman4; Shaimaa Fahim Abd El Raouf5; Reda R. Mabrouk 6
| ||||
| 1Directorate of Health Affairs in Buhaira-Clinical Research Department, Ministry of Health and Population, Damanhur, Egypt | ||||
| 2Clinical Research Administration, Alexandria Directorate of Health Affairs, Egyptian Ministry of Health and Population, Alexandria, Egypt | ||||
| 3Researchers support center, General Organization for Teaching Hospitals and institutes, Cairo, Egypt. Biostatistics department, High Institute of Public Health, Alexandria University, Egypt | ||||
| 4Critical Care and Emergency Nursing, Faculty of nursing, Damanhur university, Egypt | ||||
| 5Directorate of Health Affairs in Buhaira Clinical Research Department, Ministry of Health and Population, Damanhur, Egypt | ||||
| 6Directorate of Health Affairs in Buhaira Clinical Research Department, Ministry of Health and Population, Damanhur, Egypt Pharmaceutical medicinal chemistry and drug design department, faculty of pharmacy, Al-Azhar University, Cairo, Egypt. | ||||
| Abstract | ||||
| Tocilizumab, an interleukin-6 receptor antagonist, has been utilized as a treatment for severe COVID-19 cases due to its anti-inflammatory properties. However, its effectiveness in critically ill patients remains controversial. This retrospective cohort study aimed to evaluate the effectiveness of tocilizumab in reducing mortality and improving clinical outcomes in severe or critically ill COVID-19 patients. Data from 320 patients were reviewed, with 105 meeting the inclusion criteria. Patients were divided into two groups: 72 received the standard COVID-19 treatment protocol, and 33 received tocilizumab. The tocilizumab group had a lower mortality rate (63.6%) compared to the standard protocol group (79.2%), although this difference was not statistically significant (risk difference: 15.6%; 95% CI: –4.3 to 35.5; p = 0.091). The length of hospital stay was significantly longer in the tocilizumab group (median: 11 days, IQR: 7–17) compared to the standard treatment group (median: 7.5 days, IQR: 5–12; 95% CI: 0.014–0.019; p = 0.016). Kaplan–Meier survival analysis demonstrated a statistically significant trend in favor of the tocilizumab group (p = 0.021), despite the non-significant difference in overall mortality rates. These findings suggest that tocilizumab may offer a potential survival advantage in severe COVID-19 patients, although further studies are needed to confirm its effectiveness. | ||||
| Keywords | ||||
| Tocilizumab; interleukin-6; COVID-19; and cytokine release syndrome | ||||
|
Statistics Article View: 220 PDF Download: 45 |
||||
